Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Inavolisib|DRUG: PHESGO|DRUG: Endocrine therapy
Sponsor: German Breast Group
Collaborators: Roche Pharma AG